Eli Lilly and Co (NYSE:LLY), saw an insider substantially lower his position with the company. Senior Vice President and President of Lilly Diabetes, Enrique A. Conterno sold 10,000 shares of common stock at prices ranging from $63.72 to $63.84 per share. Following this transaction, Conterno now directly holds 87,736 shares, while indirectly having 4,615 shares invested in the company through his 401k.
In addition, there are multiple hedge funds with holdings in Eli Lilly and Co (NYSE:LLY), the $70.91 billion market cap company that discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products that it manufactures and distributes its products through facilities in the United States, Puerto Rico, and 15 other countries. Jim Simons‘ Renaissance Technologies has 5,256,105 shares worth about $309.3 million invested after reporting a 26% decrease in activity last quarter; while D. E. Shaw‘s D E Shaw fund lowered it’s holdings by 11% last quarter, and now has 2,229,143 shares worth around $131 million invested in Eli Lilly and Co (NYSE:LLY).
Disclosure: The author, Daniel Forstein, holds no positions in any stocks mentioned.